PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (NASDAQ:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has received notification from The NASDAQ Stock Market LLC that the NASDAQ Listing Qualifications Panel has determined to delist the Company’s securities from The NASDAQ Capital Market. The Panel’s decision was based on the fact that the Company has not regained compliance with NASDAQ’s $1.00 per share bid price requirement.
